A0367 (MA-0211), an orally bioavailable PPARδ modulator, is the first clinical compound to emerge from Mitobridge’s mitochondrial enhancement platform. In studies with patient muscle cells and animals, A0367 improves mitochondrial function, overall energy metabolism, muscle performance and regeneration. As Duchenne is characterized by mitochondrial defects, inadequate energy supply and muscle fibrosis, intervening with A0367 may be therapeutically beneficial for all Duchenne patients, regardless of their underlying dystrophin mutation.
A preclinical study was conducted in 2017. Preclinical development continues to ready for the clinic.
This program is sponsored by Astellas Pharma.
On April 7, 2020, Astellas Pharma shared an update on clinical trial status and COVID-19.
NOT YET RECRUITING | A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD) |
JULY 2020 | Astellas Pharma Presents at the PPMD 2020 Virtual Annual ConferencePre-recorded content for PPMD's 2020 Virtual Annual Conference On-Demand Library |
JUNE 2018 | Mitobridge Presents at the PPMD 2017 Annual Conference |
